Large global market in wound care and specialty dermatology
Late preclinical / early clinical strategy within specialty pharma
Focus on high-value, prescription-only therapeutic niches
Scalable platform with a global regulatory pathway (EU and U.S. as primary markets)
Timing
Why invest now
- Clear regulatory pathway in major markets
- Strong IP strategy around formulation and indication expansion
- Capital-efficient development model
- Multiple potential exit routes via partnering or licensing
Ownership structure (illustrative)
Founders & management65%
Early investors7%
Strategic / industry investors0%
Incentive program (ESOP)0%
Free float / other28%
Share capital and ownership structure
Number of shares
A-shares 5,824,569 B-shares 47,340
Share capital
569,389.064668 SEK
Quota value
0.096968305 SEK
Number of shareholders
800+
* Figures are updated continuously. Please contact us with questions regarding the cap table and offering terms. * The Board has a mandate until the Company's AGM on 2026-06-12 to issue up to 1,000,000 B-shares. This mandate will be utilized through multiple issuances until the AGM.
Capital
Financing strategy
Current round: VC Growth / Late Seed – Series A Bridge
Use of proceeds
- Clinical development
- Regulatory preparation EU / U.S.
- Manufacturing scale-up
- Business development and partnering
Vision
Target outcome
- Value inflection through clinical milestones
- Potential for strategic licensing or M&A
- Clear path toward a commercial specialty pharma model
Highlights
Investment highlights
Clear differentiation versus existing topical treatment options
Platform potential beyond the first product
Experienced leadership and advisor network
Tier-1 VC case
The problem
Chronic and complex wounds represent a growing global healthcare burden.
Rising incidence driven by aging populations, diabetes, and improved trauma care
Limited pharmacological innovation in prescription topical wound therapies
Existing treatments often address symptoms rather than active biological modulation
High healthcare costs and reduced quality of life for patients
Outcome: A major unmet medical need with strong willingness to pay for effective prescription therapies.
Tier-1 VC case
The solution
Auxesis Pharma develops differentiated prescription topical medicines for severe and complex wound environments.
Core strategy
- A novel pharmacological mechanism applied to topical wound therapy
- Developed for use in open wounds, burns, friction injuries, and complex skin lesions
- Optimized for regulatory approval in the EU and U.S., with global expansion potential
Platform potential
- Indication expansion across multiple wound and dermatology segments
- Lifecycle management through formulation and indication strategy
Why now
- The global wound care market is growing rapidly
- Regulatory pathways for prescription topical medicines are well-established
- Growing demand for cost-effective outpatient solutions
- Strong demand from pharma companies for de-risked specialty assets
Roadmap
Development and value creation plan
Near-term milestones
- Progress in clinical development
- Regulatory dialogue EU / U.S.
- Manufacturing readiness
Mid-term value drivers
- Clinical proof-of-concept data
- Partnering and licensing discussions
- Indication expansion strategy
Business model
- Asset-centric specialty pharma model
- Value creation through clinical de-risking
- Revenue via licensing, co-development, or strategic acquisition
Market potential
- Large and growing global wound care market
- Premium pricing potential for prescription pharmacological solutions
- Strong reimbursement potential in the EU and U.S.
Competitive advantages
- Pharmacologically driven wound therapy versus passive topical care
- Strong IP strategy around formulation and use
- Capital-efficient development pathway
- Global-first regulatory strategy
Exit
Exit opportunities
- Strategic licensing following clinical value inflection
- Acquisition by a specialty pharma or wound care player
- Opportunity to build a multi-asset company
Vision
The vision
To build a global specialty pharma company focused on high-value, prescription topical therapies for severe wound and dermatology indications.